Drugs / EDP-297
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04559126 | Sep 2020 → Jun 2021 | metabolic dysfunction-associated steatohepatitis | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-10-04 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs enanta.com ↗
A pre-planned interim analysis of a subset of patients through week 12 in the Phase 2b ARGON-2 study of EDP-305 as a monotherapy and data from its Phase 1 clinical study of EDP-297 provided meaningful information on dose selection and characterization for these compounds. |
| 2020-08-28 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress™ 2020 enanta.com ↗
Preclinical Findings for Follow-on FXR Agonist EDP-297 Targeting NASH, Demonstrating Potent Anti-Fibrotic, Anti-Inflammatory and Hepatoprotective Effects |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-10-04 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs enanta.com ↗ |
| 2020-09-14 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis enanta.com ↗ |
| 2020-08-28 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress™ 2020 enanta.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP-297 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04559126 ↗ |
| Action | Activate | “EDP-297 is a farnesoid X receptor agonist” PMID 36369848 ↗ Nov 2022 |
| Route | Oral | “orally administered single and multiple doses of EDP-297” NCT04559126 ↗ |